Search Results 1631-1640 of 19432 for hemoglobin

1. Novel HSF1 Pathway Inhibitor NXP800 In Patients with Advanced Cholangiocarcinoma - Mayo Clinic

   * Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (obtained ≤ 14 days prior to ...

2. A Phase 1 Study Of The Safety And Tolerability Of MT-125 In GBM Patients - Mayo Clinic

   Hemoglobin ≥9.0 g/dL 2. Absolute neutrophil count (ANC) ≥1500/mm3 3. Platelet count ≥100,000/mm3 4. Total bilirubin ≤1.5 x upper limit of normal (ULN) 5 ...

3. PR3-AAV Resilient Remission or PRRR - Mayo Clinic

   ... hemoglobin < 7 gm/dl or platelet count < 100,000/?l - Aspartate aminotransferase or alanine aminotransferase or amylase > 2.5 times the upper limit of ...

4. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (obtained within 21 days prior to registration);; Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN) (obtained ...

5. Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

   Hemoglobin ≥9.0 g/dL. Total bilirubin ≤1 x ULN; or total bilirubin ≤3.0 x ULN with direct bilirubin ≤1.5 x ULN in patients with well-documented ...

6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - Mayo Clinic

   hemoglobin greater than or equal to 9 g/dl;; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times the upper limit of normal ...

7. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients - Mayo Clinic

   Hemoglobin >= 9 g/dl; Serum total bilirubin =< 1.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ...

8. Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment). Renal. Serum creatinine OR Measured or calculated ...

9. Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF - Mayo Clinic

   Diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) > 30%predicted value within 4 weeks of Screening. Life expectancy of at least 12 ...

10. A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma - Mayo Clinic

    Hemoglobin ≥ 8 g/dL (may be supported) within 7 days prior to enrollment. Patients with a known seizure disorder should be stable and should have not ...